Powered by IST's

A moderately good start to the year and climbing Sp has been lost after they ann a problem with major drugs co SKB ( DYOR )...it seems previous deals have been rather poor, with VEC getting rather little for "better" powders. Now they appear to have the inhaler/delivery improved further. . . you'd expect that would mean they'd share the profits - but it seems there is an issue and SKB have the upper hand ( Unless VEC can find ANOther to distribute the product . . . makes me wonder if BTG Sales force couldn't do this as they should by now have the warehousing ).
One wonders if the income won't dip in the short-term meaning there will be a cash-call - Oh dear.
Their products appear to be good-enough against existing puffers . . . . but to get the Market excited, I think they need to make it far clearer how these differ and why one model is better-suited, compared with another they make . . .otherwise it looks like clutter, to my mind.
8 Sept 2016...sp ~150p
EDIT (24April2017)-sp ~150p nothing worthwhile to report, I guess.
EDIT(20Oct2018)-oh dear sp 70p ish.... mighty fallen... anyone?
EDIT (25NoV2018)- Seems VEC's sp was hardly knocked with the failure of asthma-trial . . . you'd think just giving a puff to someone with asthma would show if it worked - if not, then move-on. Why put money into Trials if it didn't hold great promise?